Singlera Genomics and Breakthrough Genomics launched a preclinical collaboration with the University of Pittsburgh to evaluate the BT‑Reveal early pancreatic cancer test, a methylation‑based cell‑free DNA assay. The partnership will run a preclinical validation ahead of a planned longitudinal FDA study for screening high‑risk populations. BT‑Reveal uses methylation signatures analyzed on Singlera’s mTitan platform; Breakthrough operates the CLIA lab offering the test to high‑risk patients under a breakthrough device designation. The collaboration aims to refine analytic performance and support regulatory pathways for earlier detection of pancreatic cancer—one of the diseases where cancer screening technology could materially shift outcomes.